Sensorineural hearing loss: a reversible effect of vigabatrin
| Autor: | C. Frimas, E. Papadeas, C. Paschalis, P. Papathanasopoulos, P. Polychronopoulos, N. Pharmakakis |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Neurology genetic structures Adolescent medicine.medical_treatment Hearing Loss Sensorineural Vision Disorders Vigabatrin Epilepsy Audiometry Internal medicine Ophthalmology medicine Outpatient clinic Humans business.industry Recovery of Function medicine.disease Central Hearing Loss Anticonvulsant Endocrinology GABAergic Sensorineural hearing loss Anticonvulsants Neurology (clinical) Epilepsies Partial business medicine.drug |
| Zdroj: | Neurology. 61(7) |
| ISSN: | 1526-632X |
| Popis: | Vigabatrin, a GABAergic antiepileptic drug, has been used successfully for the treatment of patients with partial epilepsy. Vigabatrin irreversibly inhibits γ-aminobutyric acid (GABA) transaminase with resultant increased concentrations of GABA in the brain and retina.1 Visual field concentric constriction secondary to vigabatrin is a frequent side effect and in most cases is irreversible.2 It has been speculated that the underlying mechanism is either a direct effect of vigabatrin on the ganglion cells of the retina or a cytotoxic effect of a possible increased GABA concentration on retina cells.3 There have been no reports of an association between the use of vigabatrin and sensorineural hearing loss. We report a patient who developed progressive hearing loss and visual field constriction after 4 years of therapy with vigabatrin for partial epilepsy. A 14-year-old boy with a 9-year history of partial epilepsy presented to the University Neurology outpatient clinic at the end of July 2002 with a moderate (50 to 55 dB HL) bilateral sensorineural hearing loss … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|